Exscientia Beheer

Beheer criteriumcontroles 1/4

De CEO Exscientia is Dave Hallett, benoemd in Feb2023, heeft een ambtstermijn van 1.75 jaar. bezit rechtstreeks 0.001% van de aandelen van het bedrijf, ter waarde € 7.00K. De gemiddelde ambtstermijn van het managementteam en de raad van bestuur bedraagt respectievelijk 1.8 jaar en 3.8 jaar.

Belangrijke informatie

Dave Hallett

Algemeen directeur

n/a

Totale compensatie

Percentage CEO-salaris	n/a
Dienstverband CEO	1.8yrs
Eigendom CEO	0.001%
Management gemiddelde ambtstermijn	1.8yrs
Gemiddelde ambtstermijn bestuur	3.8yrs

Recente managementupdates

Recent updates

CEO

Dave Hallett (55 yo)

1.8yrs

Tenure

Dr. David Hallett, also known as Dave, Ph.D. is the Chief Operations Officer of Exscientia Limited since January 2020. He served as Chief Operating Officer at Exscientia plc since June 2022 until 2022 and...

Leiderschapsteam

Naam	Positie	Tenure	Compensatie	Eigendom
David Hallett	Chief Scientific Officer	1.8yrs	geen gegevens	0.0011% € 7.0k
John Overington	Chief Technology Officer	less than a year	geen gegevens	0.015% € 91.1k
Sara Sherman	Vice President of Investor Relations	no data	geen gegevens	geen gegevens
Dan Ireland	Executive VP of Legal & Company Secretary	1.8yrs	geen gegevens	geen gegevens
Parker Moss	Executive Vice President of Corporate Development	less than a year	geen gegevens	geen gegevens
Caroline Rowland	Chief People Officer	2.2yrs	geen gegevens	geen gegevens
Richard Law	Chief Business Officer	no data	geen gegevens	geen gegevens
Nikolaus Krall	Executive Vice President of Precision Medicine	1.8yrs	geen gegevens	geen gegevens
Marie-Louise Fjallskog	Interim Chief Medical Officer & Clinical Development Lead	less than a year	geen gegevens	geen gegevens

1.8yrs

Gemiddelde duur

Ervaren management: Het managementteam van 0RK wordt niet als ervaren beschouwd (gemiddelde ambtstermijn 1.8 jaar), wat duidt op een nieuw team.

Bestuursleden

Naam	Positie	Tenure	Compensatie	Eigendom
David Hallett	Chief Scientific Officer	less than a year	geen gegevens	0.0011% € 7.0k
Elizabeth Crain	Independent Non-Executive Chairman	3.8yrs	UK£282.03k	0.088% € 535.2k
Mario Polywka	Independent Non-Executive Director	7.2yrs	UK£201.69k	0.052% € 317.2k
Robert Ghenchev	Independent Non-Executive Director	4.5yrs	geen gegevens	geen gegevens
Franziska Michor	Independent Director	1.5yrs	UK£178.86k	0.028% € 168.7k

3.8yrs

Gemiddelde duur

55yo

Gemiddelde leeftijd

Ervaren bestuur: De raad van bestuur van 0RK wordt beschouwd als ervaren (gemiddelde ambtstermijn 3.8 jaar).

Exscientia Beheer

Beheer criteriumcontroles 1/4

Belangrijke informatie

Recente managementupdates

Exscientia Appoints New Leaders to Strengthen the Impact of Integrated Technologies and Focus Clinical Development Expertise in Oncology

Exscientia plc, Annual General Meeting, May 15, 2024

Parker Moss to Join Exscientia as EVP, Corporate Development

Exscientia plc Appoints Harvard Professor Franziska Michor to Board of Directors

Exscientia plc Welcomes Caroline Rowland as Chief People Officer

Exscientia plc, Annual General Meeting, May 18, 2022

Recent updates

Recursion Pharmaceuticals, Inc. (NasdaqGS:RXRX) completed the acquisition of Exscientia plc (NasdaqGS:EXAI).

Recursion Pharmaceuticals, Inc. (NasdaqGS:RXRX) completed the acquisition of Exscientia plc (NasdaqGS:EXAI).

Third quarter 2024 earnings released: UK£0.40 loss per share (vs UK£0.25 loss in 3Q 2023)

Second quarter 2024 earnings released: US$0.36 loss per share (vs US$0.37 loss in 2Q 2023)

Exscientia plc Reports Impairment for the Second Quarter Ended June 30, 2024

Recursion Pharmaceuticals, Inc. (NasdaqGS:RXRX) entered into a transaction agreement to acquire Exscientia plc (NasdaqGS:EXAI) for approximately $640 million.

Recursion Pharmaceuticals, Inc. (NasdaqGS:RXRX) entered into a transaction agreement to acquire Exscientia plc (NasdaqGS:EXAI) for

New major risk - Revenue and earnings growth

The Schall Law Firm Announces Class Action Lawsuit Against Exscientia plc

Exscientia Appoints New Leaders to Strengthen the Impact of Integrated Technologies and Focus Clinical Development Expertise in Oncology

First quarter 2024 earnings released: US$0.21 loss per share (vs US$0.38 loss in 1Q 2023)

Exscientia plc to Report Q1, 2024 Results on May 21, 2024

Holzer & Holzer, LLC Files Class Action Lawsuit on Behalf of Exscientia P.L.C. Investors

Exscientia plc, Annual General Meeting, May 15, 2024

New minor risk - Shareholder dilution

Exscientia plc has filed a Follow-on Equity Offering in the amount of $150 million.

Exscientia plc has filed a Follow-on Equity Offering in the amount of $150 million.

Full year 2023 earnings released: UK£1.18 loss per share (vs UK£0.97 loss in FY 2022)

Exscientia plc to Report Fiscal Year 2023 Results on Mar 21, 2024

New minor risk - Shareholder dilution

Third quarter 2023 earnings released: UK£0.25 loss per share (vs UK£0.29 loss in 3Q 2022)

Exscientia plc to Report Q3, 2023 Results on Nov 09, 2023

Parker Moss to Join Exscientia as EVP, Corporate Development

Exscientia plc to Present New Preclinical Data for AI- Designed LSD1 and MALT1 Inhibitors at ESMO 2023

New minor risk - Shareholder dilution

Second quarter 2023 earnings released: US$0.37 loss per share (vs US$0.29 loss in 2Q 2022)

Exscientia plc to Report Q2, 2023 Results on Aug 10, 2023

Exscientia plc Initiates Prospective Observational Study in Ovarian Cancer

Exscientia plc Announces First Patient Enrolled in Phase 1/2 ELUCIDATE Trial Assessing GTAEXS617 in Advanced Solid Tumours

First quarter 2023 earnings released: US$0.38 loss per share (vs US$0.17 loss in 1Q 2022)

Exscientia plc Highlights "The Future of AI-Enabled Drug Discovery" at SLAS Europe

Exscientia plc to Report Q1, 2023 Results on May 24, 2023

Exscientia plc Appoints Harvard Professor Franziska Michor to Board of Directors

Full year 2022 earnings released: UK£0.97 loss per share (vs UK£0.99 loss in FY 2021)

Exscientia Announces First-in-Human Study for Bristol Myers Squibb In-Licensed PKC Theta Inhibitor, EXS4318

Exscientia plc Highlights New Data to Identify Patients That Are More Likely to Respond to Its A2a Receptor Antagonist, Exs-21546

Exscientia plc Receives First clinical trial application Approval to Initiate IGNITE-AI, Phase 1/2 Trial of EXS-21546 in Patients with Advanced Solid Tumours

Exscientia plc to Report Q3, 2022 Results on Nov 15, 2022

Blood Cancer Discovery Publication Further Validates Exscientia's Ai Precision Medicine Platform for Improving Patient Outcomes

Exscientia plc Welcomes Caroline Rowland as Chief People Officer

Second quarter 2022 earnings released: UK£0.23 loss per share (vs UK£0.71 loss in 2Q 2021)

Exscientia plc to Report Q2, 2022 Results on Aug 17, 2022

Exscientia plc Reports Data from EXS-21546 Phase 1A Study Demonstrating Targeted A2A Receptor Signaling Inhibition in Healthy Volunteers

Exscientia plc to Report Q1, 2022 Results on May 25, 2022

Exscientia plc, Annual General Meeting, May 18, 2022

Exscientia plc Appoints Michael Krams as Chief Quantitative Medicine Officer

No independent directors

Third quarter 2021 earnings released: UK£0.059 loss per share

CEO

Tenure

Leiderschapsteam

Gemiddelde duur

Bestuursleden

Gemiddelde duur

Gemiddelde leeftijd